Clinical Trial Update: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating NT-I7 after CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma has completed. The trial explored safety a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• NT-I7

Snippet

Sponsor: NeoImmuneTech | Conditions: Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Status: COMPLETED